Teladoc and LifeMD have partnered with Gifthealth, Eli Lilly's pharmacy partner, to provide access to the weight-loss drug Zepbound, currently available through LillyDirect.

Eli Lilly announced a plan to invest at least $27 billion in new U.S. manufacturing sites to meet the rising demand for its weight loss and diabetes drugs, amidst a backdrop of reshoring manufacturing and enhancing supply chains.

Eli Lilly has introduced higher-dose vials of its weight loss drug Zepbound at reduced prices to improve access for uninsured patients and those on Medicare, amidst rising demand and an end to the drug's shortage.